Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis

[11] Hesketh PJ(2018)A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) Annals of Oncology 29 452-458

[12] Jordan K(2016)Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison Oncotarget 7 24402-24414

[13] Olver I(2016)Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis Ther Adv Med Oncol 8 396-406

[14] Rapoport BL(2017)Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen Journal of Clinical Oncology 35 120-120

[15] Roscoe J(2017)NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK Drugs Context 6 212298-307

[16] Ruhlmann CH(2007)Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany Eur J Cancer 43 299-181

[17] Walsh D(2016)Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system Breast Cancer: Targets and Therapy Volume 8 173-319

[18] Warr D(1994)Costs, effects and C/E-ratios alongside a clinical trial Health Econ 3 309-333

[19] van der Wetering M(1999)Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis Health Econ 8 323-98

[20] Sun CC(2015)A Monte Carlo method to estimate the confidence intervals for the concentration index using aggregated population register data Health Serv Outcome Res Methodol 15 82-851

[11] Hesketh PJ(2018)A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) Annals of Oncology 29 452-458

[12] Jordan K(2016)Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison Oncotarget 7 24402-24414

[13] Olver I(2016)Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis Ther Adv Med Oncol 8 396-406

[14] Rapoport BL(2017)Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen Journal of Clinical Oncology 35 120-120

[15] Roscoe J(2017)NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK Drugs Context 6 212298-307

[16] Ruhlmann CH(2007)Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany Eur J Cancer 43 299-181

[17] Walsh D(2016)Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system Breast Cancer: Targets and Therapy Volume 8 173-319

[18] Warr D(1994)Costs, effects and C/E-ratios alongside a clinical trial Health Econ 3 309-333

[19] van der Wetering M(1999)Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis Health Econ 8 323-98

[20] Sun CC(2015)A Monte Carlo method to estimate the confidence intervals for the concentration index using aggregated population register data Health Serv Outcome Res Methodol 15 82-851